Omeprazole Injection 40mg GMP Medicine

Product Details
Customization: Available
Application: Oral
Usage Mode: Injection
Still deciding? Get samples of US$ 0/Piece
Request Sample
Manufacturer/Factory, Trading Company

360° Virtual Tour

Diamond Member Since 2015

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Years of Export Experience
The export experience of the supplier is more than 10 years
High Repeat Buyers Choice
More than 50% of buyers repeatedly choose the supplier
Importers and Exporters
The supplier has import and export rights
Management Certification
The supplier has quality management system certification, including:
ISO9001:2015 certificate
ISO45001:2018 certificate
ISO14001
to see all verified strength labels (20)
  • Omeprazole Injection 40mg GMP Medicine
  • Omeprazole Injection 40mg GMP Medicine
  • Omeprazole Injection 40mg GMP Medicine
  • Omeprazole Injection 40mg GMP Medicine
  • Omeprazole Injection 40mg GMP Medicine
  • Omeprazole Injection 40mg GMP Medicine
Find Similar Products

Basic Info.

Model NO.
AMC13025
Suitable for
Elderly, Adult
State
Lyophilized Powder
Shape
Powder
Type
Biological Products
Pharmaceutical Technology
Chemical Synthesis
Transport Package
Box, Carton
Specification
40mg
Trademark
Medipharm or OEM
Origin
China
HS Code
3004909099
Production Capacity
500000/Month

Product Description

Omeprazole Injection 40mg GMP Medicine
 
Application Internal Medicine
Suitable for  Elderly, Adult
Shape Powder
Usage Mode For oral administration
State Solid
Type Organic Chemicals

character
This product is white or off-white loose lump or powder.
Indications
As an alternative therapy for the following conditions when oral therapy is not indicated: duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome.
Specification 
40mg (calculated as C17H19N3O3S)

Dosage 
Intravenous infusion: before use, dissolve the contents of the bottle in 100 ml of 0.9% sodium chloride injection or 100 ml of 5% glucose injection. After dissolving this product, the intravenous infusion time should be 20-30 minutes or more long. It is forbidden to dissolve and dilute with other solvents or other drugs.
When oral therapy is not suitable for patients with duodenal ulcer, gastric ulcer and reflux esophagitis, the recommended dose of intravenous infusion of this product is 40mg, once a day.
For patients with Zollinger-Ellison syndrome, intravenous infusion of omeprazole 60 mg is recommended as the starting dose, once a day. Patients with Zollinger-Ellison syndrome may require a higher daily dose, and the dose should be individualized. When the daily dose exceeds 60 mg, it is administered in two doses.

adverse reaction 
Omeprazole was well tolerated, and adverse reactions were mostly mild and reversible. The following adverse reactions were reported in clinical trials or routine use, but in many cases the causal relationship with omeprazole treatment itself has not been established.
Among the following adverse reactions:
"Common" means incidence ≥ l/100
"Uncommon" refers to an incidence ≥l/1000, but <1/100
"Rare" refers to an incidence of <1/1000
It has been reported in the literature that irreversible visual damage occurred in a critically ill patient after receiving high-dose intravenous injection of omeprazole.
Taboo
Those who are allergic to this product are prohibited.

Precautions 
1. This product has a strong inhibitory effect on gastric acid secretion and lasts for a long time, so it is not advisable to take other antacids or antacids at the same time when using this product. In order to prevent excessive acid suppression, long-term application of large doses is not recommended in general peptic ulcer and other diseases (except for patients with Zollinger-Ellison syndrome). 2. Because this product can significantly increase the pH value in the stomach, it may affect the absorption of many drugs.
3. Patients with impaired renal function do not need to adjust the dose; patients with impaired liver function should use it with caution and reduce the dose as needed.
4. When treating gastric ulcer, gastric cancer should be ruled out before using this product, so as not to delay diagnosis and treatment.
5. If the patient takes proton pump inhibitors for a long time, during the medication process, attention should be paid to the possible fracture risk (especially in elderly patients), and the blood magnesium level should be monitored regularly to prevent the occurrence of hypomagnesemia.
6. Due to the interaction between proton pump inhibitors and clopidogrel, it is recommended that patients who are using clopidogrel communicate with their doctors about drug safety issues before treatment to ensure drug safety.
Drugs for pregnant and lactating women
Although animal experiments have not found that this product has adverse effects on pregnancy and lactation, or has toxic or teratogenic effects on the fetus, it is recommended that pregnant and lactating women should not use it as much as possible.

Medication for Children 
There is currently no experience with this product in children.

Geriatric medication
Elderly patients do not need to adjust the dose.
Drug Interactions Report
Because this product can reduce the acidity in the stomach, the absorption of some drugs may be altered. The absorption of ketoconazole and itraconazole may therefore be decreased during treatment with omeprazole or other acid inhibitors or antacids.
Since omeprazole is metabolized by cytochrome F4502C19 (CYP2C19) in the liver, it will prolong the clearance of other enzymatic hydrolyzates such as diazepam, warfarin (R-warfarin) and phenytoin. This product should be monitored during treatment with warfarin and phenytoin, and the dose of warfarin or phenytoin should be reduced if necessary. Patients who continued to use phenytoin were given 20 mg of this product once a day at the same time, and the plasma concentration of phenytoin was not affected. Similarly, patients who continued to use warfarin therapy while giving this product 20mg once a day did not change the coagulation time.
When omeprazole is co-administered with clarithromycin, their blood levels increase. However, when it is used in combination with metronidazole or amoxicillin, there is no interaction. These antibiotics are used in combination with omeprazole to eradicate H. pylori.
drug overdose
In clinical trials, the cumulative dose of this product reached 270mg on one day and 650mg on three days by intravenous administration, and no dose-related adverse reactions occurred.


Omeprazole Injection 40mg GMP MedicineOmeprazole Injection 40mg GMP MedicineOmeprazole Injection 40mg GMP MedicineOmeprazole Injection 40mg GMP MedicineOmeprazole Injection 40mg GMP MedicineOmeprazole Injection 40mg GMP Medicine


 

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier